

# SEQUENCE LISTING

<110> Richard B. Moss  
 <110> Akitoshi Ishizaka  
 <110> Teruo Kirikae

<120> Method for Assessment of Cystic Lung Fibrosis

<130>

<140>

<141>

<150> US 60/447,310  
 <151> 2003-02-14

<160> 4

<170> PatentIn version 3.1

<210> 1

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> This peptide was used as an antigen.

<400> 1

Phe	Arg	Lys	Ser	Lys	Glu	Lys	Ile	Gly	Lys	Glu	Phe	Lys	Arg	Ile	Val
1				5				10						15	
Gln	Arg	Ile	Lys	Asp	Phe	Leu	Arg	Asn	Leu	Val					
			20					25							

<210> 2

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> This peptide was used as an antigen.

<400> 2

Lys	Glu	Phe	Lys	Arg	Ile	Val	Gln	Arg	Ile	Lys	Asp	Phe	Leu	Arg	Asn
1				5				10						15	
Leu	Val														

<210> 3

<211> 9  
 <212> PRT  
 <213> Artificial Sequence  
 <220>  
 <223> This peptide was used as an antigen.

<400> 3  
 Phe Arg Lys Ser Lys Glu Lys Ile Gly  
 1 5

<210> 4  
 <211> 170  
 <212> PRT  
 <213> Homo sapiens

<400> 4  
 Met Lys Thr Gln Arg Asn Gly His Ser Leu Gly Arg Trp Ser Leu Val  
 1 5 10 15  
 Leu Leu Leu Leu Gly Leu Val Met Pro Leu Ala Ile Ile Ala Gln Val  
 20 25 30  
 Leu Ser Tyr Lys Glu Ala Val Leu Arg Ala Ile Asp Gly Ile Asn Gln  
 35 40 45  
 Arg Ser Ser Asp Ala Asn Leu Tyr Arg Leu Leu Asp Leu Asp Pro Arg  
 50 55 60  
 Pro Thr Met Asp Gly Asp Pro Asp Thr Pro Lys Pro Val Ser Phe Thr  
 65 70 75 80  
 Val Lys Glu Thr Val Cys Pro Arg Thr Thr Gln Gln Ser Pro Glu Asp  
 85 90 95  
 Cys Asp Phe Lys Lys Asp Gly Leu Val Lys Arg Cys Met Gly Thr Val  
 100 105 110  
 Thr Leu Asn Gln Ala Arg Gly Ser Phe Asp Ile Ser Cys Asp Lys Asp  
 115 120 125  
 Asn Lys Arg Phe Ala Leu Leu Gly Asp Phe Phe Arg Lys Ser Lys Glu  
 130 135 140  
 Lys Ile Gly Lys Glu Phe Lys Arg Ile Val Gln Arg Ile Lys Asp Phe  
 145 150 155 160  
 Leu Arg Asn Leu Val Pro Arg Thr Glu Ser  
 165 170